Project description
Kaposi’s sarcoma and RNA-binding proteins: from virus biology to targeted therapies
Kaposi’s sarcoma-associated herpesvirus (KSHV) causes Kaposi’s sarcoma, a type of cancer in the skin and the gastrointestinal tract, and two lymphomas: multicentric Castleman’s disease and primary effusion lymphoma. KSHV is a DNA virus that establishes a lifelong latent and persistent infection in endothelial and B cells. Reactivation produces new viral particles allowing transmission to other individuals. Insight into KSHV infection and pathogenesis will help develop targeted antiviral drugs. Funded by the Marie Skłodowska-Curie Actions programme, the KSHV-RBPome project will investigate the role of viral and host RNA-binding proteins (RBPs) in the latent infection and reactivation of KSHV. Researchers aim to generate a comprehensive catalogue of RBPs affecting the virus and to develop targeted antivirals against viral RBPs using RNA-based technologies.
Objective
Kaposi’s sarcoma-associated herpesvirus (KSHV), an oncogenic human γ-herpesvirus, is the cause of Kaposi’s Sarcoma (KS), primary effusion lymphoma and multicentric Castleman's disease with no effective therapies. Like other herpesviruses, KSHV has a latent cycle with limited gene expression and a lytic cycle with expression of most viral genes and production of infectious viral particles. RNA-binding proteins (RBP) play key roles in RNA biology, including expression, export, stability, processing and translation. Previous reports showed that RBPs can function as proviral or antiviral. Viruses also express viral RBPs. There are no reports investigating the role of RBPs during infection with DNA viruses. Here we aim to determine the scope of host and viral RBPs involved in KSHV latent infection and reactivation. To do so, we will employ a multidisciplinary approach that combines cutting edge methods of molecular biology and virology with next generation technologies to discover cellular RBPs that directly interact with viral RNA and regulate KSHV infection and tumorigenesis. We expect also to discover novel viral RBPs involved in KSHV infection and pathogenesis. The outcome of this project will be a comprehensive census of RBPs with antiviral, proviral and pro-oncogenic activities. In the short-term, the knowledge obtained will facilitate the development of biotechnological applications to exploit the function of RBPs in RNA biology, including RNA visualization, expression and translation. In the long-term, the proviral RBPs could be targeted to develop host-based antivirals. Therefore, this project contributes to the EU global challenge of Health and the EU Mission Cancer. To ensure the successful outcome of this project, I will contribute with my experience in molecular virology and my supervisors will train me in system-wide profiling of RBPs and cutting-edge methods in virology, ensuring the appropriate transfer of knowledge among the participants.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- social sciences sociology demography census
- medical and health sciences clinical medicine oncology
- natural sciences biological sciences genetics RNA
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antivirals
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-MSCA-2022-PF-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
30625 Hannover
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.